Quantum biopharma announces completion of dosing in 90-day repeated dose oral toxicity and toxicokinetic studies for lucid-ms for multiple sclerosis

Toronto, may 12, 2025 (globe newswire) -- quantum biopharma ltd. (nasdaq: qntm) (cse: qntm) (fra: 0k91) (“quantum biopharma” or the “company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studies for lucid-21-302 (lucid-ms) for multiple sclerosis (“ms”). these studies were commissioned to provide data to support an ind application with the us fda.
QNTM Ratings Summary
QNTM Quant Ranking